Development of drug resistance [1, 2] and clonal evolution [3] [4] [5] is a major problem in multiple myeloma (MM) but its comprehensive longitudinal genetic characterization has been impractical thus far. We asked if copy number variations (CNV) and somatic mutations can be called robustly across the entire genome or exome, from cell-free DNA (cfDNA) in patients with active disease, and if clonal somatic mutations and CNVs found in the bone marrow (BM) are reliably reproduced by cfDNA. We hypothesized that (i) the subclonal composition of somatic mutations and CNVs differs, indicating that cfDNA and BM MM cells reveal distinct genetic information [6, 7] and (ii) cfDNA can be used to track disease load and clonal evolution of MM, to provide longitudinal genetic information about disease evolution that is not accessible by bone marrow biopsy [8, 9] . To first demonstrate whether low-pass whole-genome sequencing of cfDNA from MM patients is feasible, cfDNA was extracted from a total of 147 samples obtained from blood of 93 randomly selected MM patients, as well as from 12 healthy donors (Supplementary Table 1 ). We performed library construction, low-pass whole-genome sequencing (average depth of 0.22; range, 0.01-1×) and predicted segments of CNVs and estimates of tumor fraction (fraction of MM-derived cfDNA) using the ichorCNA [10] algorithm (Supplementary Figure 1) . While CNVs were readily detected in cfDNA from MM patients, no CNVs were detected in cfDNA from healthy blood donors (predicted tumor fraction <0.05). Clinical data were available for 67 of 93 patients. Of those, we found that tumor fraction was ≥0.05 (detectable) in 16/26 (62%) cfDNA samples from patients with relapsed/refractory MM and 3/4 (75%) in cfDNA samples from patients with newly diagnosed MM, while tumor fraction in cfDNA from MM patients receiving treatment (35 patients with response and 2 patients with stable disease) was <0.05 (Fig. 1a) .
To evaluate the concordance of CNVs and mutations between cfDNA and matched BM myeloma, we performed whole-exome sequencing (WES) of cfDNA, BM-derived . High concordance of CNVs was also seen between cfDNA and BM samples of nine other MM patients, even when compared between lpWGS and WES. On average, 90.5% of all CNV segments in BM were concordant with cfDNA, whereas 9.5% were discordant (Supplementary Figure 3) . To determine if mutation calls were reproducible between cfDNA and BM-derived MM, we identified all coding somatic mutations (Supplementary Table 3 ) by WES of cfDNA and BM-derived MM from 10 patients followed by determining their clonality and the fraction of MM cells harboring these mutations (cancer cell fraction). All clonal and subclonal mutations in putative myeloma driver genes (KRAS, DIS3, TP53, NRAS, and RB1) [3] [4] [5] were found in cfDNA and BM, except for one subclonal HIST1H1E mutation that was detected only in the bone marrow (Fig. 1c) . We also asked what fraction of these mutations could be detected in cfDNA from the same patients. We found a median of 93% (range, 75-100%) of clonal mutations in the bone marrow was detected in the cfDNA, either in a clonal or subclonal fashion (Fig. 1d, left panel) . Conversely, 91% (58-98%) of clonal mutations in cfDNA were also detected in BM MM cells (Fig. 1d, right panel) . These data suggest that cfDNA represents a useful proxy for CNVs and the clonal mutational landscape of MM in the BM.
We next tested if the subclonal composition in cfDNA is different from bone marrow, perhaps revealing or de-prioritizing relevant subclones. Individual clones were distinguished by performing a two-dimensional kernel density estimation and displaying the results with contours ("Materials and methods"). In the first patient, R13, there was a strong correlation of the cancer cell fractions (Pearson's correlation r = 0.901, P < 2.2 × 10 −16 ) of individual mutations between cfDNA and BM, as evidenced by two dominant subclones with a similar CCF in cfDNA and BM (Fig. 2a) . In another patient (Y2), there was a single-dominant subclone comprising nearly half of the circulating myeloma DNA. Despite greater effective sequencing depth (Supplementary Table 2 ), this subclone was only partially detectable in the BM at much lower CCF (Fig. 2b) , suggesting a different subclonal composition of cfDNA compared to BM-derived MM. In another patient Y5, we detected four independent subclones, each harboring a non-overlapping KRAS mutations (G12S, G12D, G12A, and G12C) (Fig. 2c) . Lastly, in one patient we found that the clonal composition of BM and cfDNA differed by CNVs with BM-specific allelic amplification of chromosome 5q, 7p, and 9 only in BM but not cfDNA (Supplementary Figure 4) . These data demonstrate that differences in the subclonal composition between cfDNA and MM samples obtained from a single site bone marrow biopsy exist in some cases. Although obtaining blood for genetic examination of cfDNA is safer, less costly and more convenient for the patient than BM biopsy, it is essential to estimate the success rate of comprehensive sequencing by low-pass WGS and WES of cfDNA beforehand in order to determine when to utilize this technique. Our data indicate that the cfDNA concentration can be used to estimate the expected tumor fraction in cfDNA and that the tumor fraction can be used to estimate the fraction of clonal bone marrow mutations that can be detected in cfDNA (Supplementary Figure 5) .
We finally determined the potential of cfDNA as a longitudinal marker for disease progression and therapy response. We focused on a patient responding well to the indicated therapy initially, which was evident by decreasing levels of serum-free light chains (sFLC) and concordant trajectory of tumor fraction in cfDNA (Fig. 2d, e) . We then determined the CNVs in MM-derived cfDNA before treatment (day 19, prior to cytoreduction with cyclophosphamide, bortezomib, dexamethasone), and after relapse (day 224, after maintenance with ixazomib, dexamethasone). The cfDNA copy number profiles on day 0 and day 19 (with no change in management) were concordant. Tumor fraction became undetectable with response to treatment (days 41 and 69). However, with relapse extensive clonal evolution occurred (day 224, after relapse) (Fig. 2d, f) as drug resistance developed. Importantly, the copy number profile of cfDNA and BM on day 224 were concordant (Fig. 2f) . WES with allelic resolution revealed clonal or near-clonal outgrowth of a subclone harboring allelic amplification of chromosome 6 and 12, as well as disappearance of subclones harboring allelic deletion of chromosome 7, 1, 2q, 4, 10, 13, 14, 15, 16p, 19, and 22 (Supplementary Figure 6) . Two possible solutions for the observed clonal evolution are reflected as phylogenetic trees (Supplementary Figure 7) , suggesting the selection and outgrowth of a drug-resistant subclone. These data demonstrate that cfDNA profiling may provide a powerful tool to longitudinally follow the clonal evolution of MM and the competitive emergence of drug-resistant subclones.
The studies we present demonstrate that comprehensive genomic interrogation by WES and WGS of MM-derived cfDNA is feasible and allows detailed genomic insight into MM evolution and progression over time. This may be particularly useful for elderly patients with significant comorbidities, as these patients are less likely to be subjected to frequent bone marrow biopsies or to be enrolled in clinical trials. cfDNA allows shipping from remote locations at room temperature in preservative-containing tubes and is therefore a particularly attractive alternative for this population. While the success rate of comprehensive genomic characterization by lpWGS and WES of cfDNA is high in patients with active disease, it is currently not cost-effective for patients in remission. Targeted sequencing approaches with limited genomic territory have been described [11] [12] [13] and allow greater sequencing depth at reduced cost in these cases. MRD negativity is of great interest as an end point for treatment success in MM. While the sensitivity of MRD detection in the BM is unlikely to be achieved even by targeted sequencing of cfDNA, liquid biopsy approaches, including circulating MM cells [14, 15] , may add further accuracy to progression-free survival (PFS) prediction by defining the duration of MRD negativity. lpWGS and WES of cfDNA enable detailed genomic characterization of MM to identify putative resistance mechanisms and precision medicine targets as an alternative for repeated BM biopsies.
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